published meta-analysis   sensitivity analysis   studies

hydroxychloroquine plus macrolides in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalizationdetailed resultsRodrigues, 2021 2.02 [0.07; 62.02] 2.02[0.07; 62.02]Rodrigues, 202110%84NAnot evaluable viral clearance detailed resultsQ-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61] Rodrigues, 2021 1.00 [0.42; 2.39] 0.91[0.54; 1.51]Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Rodrigues, 202120%383moderatenot evaluable viral clearance by day 14detailed resultsQ-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.55 [0.32; 0.94] 0.55[0.32; 0.94]Q-PROTECT (HCQ/AZI vs PLACEBO), 202010%292NAnot evaluable viral clearance by day 7detailed resultsQ-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61] Rodrigues, 2021 1.00 [0.42; 2.39] 0.91[0.54; 1.51]Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Rodrigues, 202120%383moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-29 11:00 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 559,889 - roots T: 290